Overview

Dificlir is a medicine used to treat children and adults with infections of the gut caused by bacteria called Clostridioides difficile.

Dificlir contains the active substance fidaxomicin.

Dificlir is available as tablets (200 mg) or granules for oral suspension (40 mg/ml) and can only be obtained with a prescription.

In adults and children weighing at least 12.5 kg, the recommended dose is 200 mg twice a day (every 12 hours) for 10 days. For children weighing less than 12.5 kg, the dose depends on the bodyweight. For more information about using Dificlir, see the package leaflet or contact your doctor or pharmacist.

C. difficile are bacteria that are present naturally in the gut and do not cause any problems in healthy people. This is because they are kept under control by other ‘good’ bacteria which are beneficial to the body and enhance health. However, some antibiotics that are used to treat infections can interfere with the balance and kill the 'good' bacteria in the gut. When this happens, C. difficile bacteria can multiply and produce toxins (poisons) which cause illness such as diarrhoea and fever. At this point, a person is said to be infected with C. difficile.

The active substance in Dificlir, fidaxomicin, is an antibiotic that belongs to the class of macrocylic antibiotics. When it is swallowed most of the active substance does not get absorbed into the blood stream but acts locally on C. difficile bacteria in the gut. It works by blocking the bacterial enzyme RNA polymerase, which is used to produce the genetic material that the bacteria need to make proteins.

This stops the C. difficile bacteria from growing and multiplying, thereby reducing the symptoms of the disease.

Dificlir was at least as effective as vancomycin (another antibiotic for C. difficile infections) in three main studies in patients with mild to moderately severe C. difficile infection. The results of two studies involving a total of 1,147 adults showed that 92% of patients taking Dificlir were cured after 10 days compared with 90% of patients taking vancomycin.

In the third study, which involved 148 patients aged from birth to 18 years, 78% of patients taking Dificlir were cured 2 days after the end of treatment, compared with 71% of patients taking vancomycin.

The most common side effects with Dificlir (which may affect up to 1 in 10 people) are nausea (feeling sick), vomiting and constipation. For the full list of side effects and restrictions with Dificlir, see the package leaflet.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dificlir have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Dificlir are continuously monitored. Side effects reported with Dificlir are carefully evaluated and any necessary action taken to protect patients.

Dificlir received a marketing authorisation valid throughout the EU on 5 December 2011.

Dificlir : EPAR - Medicine overview

български (BG) (141.03 KB - PDF)
español (ES) (110.58 KB - PDF)
čeština (CS) (131.56 KB - PDF)
dansk (DA) (110.21 KB - PDF)
Deutsch (DE) (112.45 KB - PDF)
eesti keel (ET) (107.09 KB - PDF)
ελληνικά (EL) (134.22 KB - PDF)
français (FR) (111.01 KB - PDF)
hrvatski (HR) (130.79 KB - PDF)
italiano (IT) (109.38 KB - PDF)
latviešu valoda (LV) (146.05 KB - PDF)
lietuvių kalba (LT) (131.72 KB - PDF)
magyar (HU) (130.08 KB - PDF)
Malti (MT) (141.17 KB - PDF)
Nederlands (NL) (110.14 KB - PDF)
polski (PL) (131.78 KB - PDF)
português (PT) (111.52 KB - PDF)
română (RO) (137.4 KB - PDF)
slovenčina (SK) (131.45 KB - PDF)
slovenščina (SL) (129.3 KB - PDF)
Suomi (FI) (108.1 KB - PDF)
svenska (SV) (109.29 KB - PDF)

Dificlir : EPAR - Risk-management-plan summary

Product information

Dificlir : EPAR - Product Information

български (BG) (453.44 KB - PDF)
español (ES) (317.61 KB - PDF)
čeština (CS) (420.03 KB - PDF)
dansk (DA) (305.59 KB - PDF)
Deutsch (DE) (330.56 KB - PDF)
eesti keel (ET) (303.96 KB - PDF)
ελληνικά (EL) (504.33 KB - PDF)
français (FR) (351.84 KB - PDF)
hrvatski (HR) (405.83 KB - PDF)
íslenska (IS) (313.76 KB - PDF)
italiano (IT) (325.18 KB - PDF)
latviešu valoda (LV) (405.64 KB - PDF)
lietuvių kalba (LT) (416.96 KB - PDF)
magyar (HU) (441.22 KB - PDF)
Malti (MT) (446.41 KB - PDF)
Nederlands (NL) (333.74 KB - PDF)
norsk (NO) (341.58 KB - PDF)
polski (PL) (419.77 KB - PDF)
português (PT) (307.08 KB - PDF)
română (RO) (418.88 KB - PDF)
slovenčina (SK) (415.02 KB - PDF)
slovenščina (SL) (381.54 KB - PDF)
Suomi (FI) (302.09 KB - PDF)
svenska (SV) (296.84 KB - PDF)

Latest procedure affecting product information: II/0049

12/12/2022

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

Dificlir : EPAR - All Authorised presentations

български (BG) (40.36 KB - PDF)
español (ES) (23.7 KB - PDF)
čeština (CS) (37.86 KB - PDF)
dansk (DA) (23.79 KB - PDF)
Deutsch (DE) (15.39 KB - PDF)
eesti keel (ET) (17.79 KB - PDF)
ελληνικά (EL) (37.45 KB - PDF)
français (FR) (23.93 KB - PDF)
hrvatski (HR) (42.15 KB - PDF)
íslenska (IS) (24.21 KB - PDF)
italiano (IT) (13.48 KB - PDF)
latviešu valoda (LV) (39.39 KB - PDF)
lietuvių kalba (LT) (41.38 KB - PDF)
magyar (HU) (41.25 KB - PDF)
Malti (MT) (36.5 KB - PDF)
Nederlands (NL) (23.8 KB - PDF)
norsk (NO) (23.8 KB - PDF)
polski (PL) (41.44 KB - PDF)
português (PT) (23.71 KB - PDF)
română (RO) (31.35 KB - PDF)
slovenčina (SK) (39.39 KB - PDF)
slovenščina (SL) (40.05 KB - PDF)
Suomi (FI) (23.97 KB - PDF)
svenska (SV) (24.17 KB - PDF)

Product details

Name of medicine
Dificlir
Active substance
fidaxomicin
International non-proprietary name (INN) or common name
fidaxomicin
Therapeutic area (MeSH)
Clostridium Infections
Anatomical therapeutic chemical (ATC) code
A07AA12

Pharmacotherapeutic group

Antidiarrheals, intestinal antiinflammatory / antiinfective agents

Therapeutic indication

Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Dificlir granules for oral suspension is indicated for the treatment of Clostridioides  difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.

Authorisation details

EMA product number
EMEA/H/C/002087
Marketing authorisation holder
Tillotts Pharma GmbH

Warmbacher Strasse 80
79618 Rheinfelden
Germany

Opinion adopted
22/09/2011
Marketing authorisation issued
05/12/2011
Revision
17

Assessment history

Dificlir : EPAR - Procedural steps taken and scientific information after authorisation

Dificlir-H-C-002087-X-0034-G : EPAR - Assessment Report - Extension

CHMP post-authorisation summary of positive opinion for Dificlir (X-34)

Dificlir-H-C-2087-P46-0022 : EPAR - Assessment Report

Dificlir-EMEA-H-C-2087-PSUV-0015: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Dificlir : EPAR - Public assessment report

CHMP summary of positive opinion for Dificlir

Topics

This page was last updated on

How useful do you find this page?

Average: